Grants

MT21-001: Impact of the secondary bile acid ursodeoxycholic acid (Ursodiol) on the feline gut microbiota and metabolome

Ursodiol is an FDA approved naturally occurring bile acid that is used to treat a variety of liver and gastrointestinal diseases. Ursodiol is routinely administered in veterinary medicine; however, it is unknown how this drug impacts the feline intestinal ecosystem. Evidence is mounting that bile acids, such as Ursodiol, can alter the gut microbial composition and host physiologic response during health and disease. Our study aims to determine how oral administration of Ursodiol alters the feline intestinal ecosystem, specifically the gut microbiota (collection of microorganisms that live in the intestines) and microbial metabolites (important molecules made by the gut microbes). The goal is to improve our knowledge of Ursodiol-mediated effects to the feline intestinal ecosystem to facilitate rational incorporation of Ursodiol into a personalized medicine approach for cats suffering from liver, gastrointestinal, and kidney disease in order to improve quality of life.

Grant ID: MT21-001

Status: Active

Year Funded: 2021

Amount awarded: $26,437

Investigator: Jenessa A. Winston, DVM, PhD, DACVIM; The Ohio State University College of Veterinary Medicine